Sterile Injectable Manufacturing: SOP for Reconciliation of Materials Used in Manufacturing – V 2.0
Standard Operating Procedure for Reconciliation of Materials Used in Manufacturing
| Department |
Sterile Injectable Manufacturing |
| SOP No. |
SOP/SIM/039/2025 |
| Supersedes |
SOP/SIM/039/2022 |
| Page No. |
Page 1 of 14 |
| Issue Date |
18/06/2025 |
| Effective Date |
20/06/2025 |
| Review Date |
18/06/2026 |
1. Purpose
To define a standardized procedure for reconciling all materials used in the sterile injectable manufacturing process, including active ingredients, excipients, primary and secondary packaging components, ensuring complete traceability and compliance with cGMP requirements.
2. Scope
This SOP applies to all sterile injectable manufacturing batches processed within the facility, covering raw materials, consumables, primary packaging, and secondary packaging used from dispensing through final batch completion.
3. Responsibilities
- Manufacturing Executive: Performs reconciliation during and after batch operations and records details in BMR.
- QA Executive: Verifies and cross-checks reconciliation data and ensures compliance with acceptable variance limits.
- Warehouse Personnel: Supports material issuance and returns with traceable documentation.
- Production Supervisor: Ensures physical verification and accuracy of reconciled materials.
4. Accountability
The Head of Production is accountable for the accuracy, completeness, and verification of all material reconciliation activities in the sterile injectable manufacturing area.
5. Procedure
5.1 Material Reconciliation Types
- Raw Material Reconciliation: Reconciliation of active pharmaceutical ingredients (API) and excipients used during formulation.
- Packaging Material Reconciliation: Reconciliation of vials, stoppers, seals, labels, cartons, etc.
5.2 During Batch Processing
- Verify that the correct quantities of all materials are issued and recorded in the BMR.
- Update real-time usage of each component at respective processing stages (e.g., solution preparation, filtration, filling, sealing).
- Record any spillage, breakages, line clearance wastage, and overages under appropriate loss categories in the BMR.
- Perform intermediate reconciliation at major stages (e.g., post-filling, post-sealing).
5.3 Post-Batch Completion
- Calculate the theoretical quantity of materials based on the approved batch size and yield.
- Compare with actual used quantities and returned excess materials.
- Account for yield losses under defined categories: process loss, handling loss, line loss, etc.
- Document in the Material Reconciliation Sheet (Annexure-1).
5.4 Acceptable Variance Limits
- For APIs: ±2%
- For Excipients: ±3%
- For Packaging Materials: ±5%
- Deviation beyond limits must be investigated and deviation form raised (Annexure-2).
5.5 Final Reconciliation Review
- QA reviews reconciled data and signs off reconciliation report.
- Materials with confirmed reconciliation can be closed in inventory records.
- Retain completed reconciliation reports with BMR for a minimum of 5 years.
6. Abbreviations
- API: Active Pharmaceutical Ingredient
- BMR: Batch Manufacturing Record
- QA: Quality Assurance
- SOP: Standard Operating Procedure
7. Documents
- Material Reconciliation Sheet – Annexure-1
- Deviation Form – Annexure-2
- Batch Yield Summary – Annexure-3
8. References
- WHO TRS 986 Annex 2 – GMP for Pharmaceutical Products
- EU GMP Volume 4, Part 1: Chapter 5 – Production
- 21 CFR Part 211.103 – Calculation of yield
9. SOP Version
Version: 2.0
10. Approval Section
|
Prepared By |
Checked By |
Approved By |
| Signature |
|
|
|
| Date |
|
|
|
| Name |
|
|
|
| Designation |
Manufacturing Executive |
QA Executive |
Head QA |
| Department |
Production |
Quality Assurance |
Quality Assurance |
11. Annexures
Annexure-1: Material Reconciliation Sheet
| Material |
Issued Qty |
Used Qty |
Returned |
Loss Qty |
Remarks |
| Sodium Chloride |
25 kg |
24.2 kg |
0.5 kg |
0.3 kg |
Line loss recorded |
Annexure-2: Deviation Form
| Date |
Batch No. |
Material |
Variance (%) |
Deviation No. |
Action Taken |
| 18/06/2025 |
IV-1025 |
API |
2.8% |
DEV-093 |
Investigated and justified |
Annexure-3: Batch Yield Summary
| Batch No. |
Theoretical Yield |
Actual Yield |
Variance (%) |
Remarks |
| IV-1025 |
5000 vials |
4875 vials |
2.5% |
Acceptable range |
Revision History
| Revision Date |
Revision No. |
Details |
Reason |
Approved By |
| 10/04/2022 |
1.0 |
Initial version |
New SOP |
QA Head |
| 18/06/2025 |
2.0 |
Updated reconciliation categories and annexures |
Annual SOP Review |
QA Head |